Mereo BioPharma Group plc (MAH0) — Capital Reinvestment Ratio

Latest as of June 2021: 0.05x

Mereo BioPharma Group plc (MAH0) has a Capital Reinvestment Ratio of 0.05x as of June 2021, meaning it reinvests 0% of its operating cash flow (€4.95 Million) in capital expenditures (€267.50K). See Mereo BioPharma Group plc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.05x

Capex / Operating Cash Flow

Operating Cash Flow

€4.95 Million

EUR

Capital Expenditures

€267.50K

EUR

Data as of

Jun 2021

Most recent filing

Annual Capital Reinvestment Ratio for Mereo BioPharma Group plc (None–None)

Year-by-year Capital Reinvestment Ratio for Mereo BioPharma Group plc from None to None. For live market cap and broader valuation context, see Mereo BioPharma Group plc market capitalisation.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow